Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib in chronic phase chronic myelogenous leukemia
NCT05384587Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2022
- Primary completion
- Aug 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of asciminib in chronic myelogenous leukemia (CML), sponsored by Novartis. Started Nov 2022; status: active, not recruiting.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT05384587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05384587.